MedPath

Physiologic Assessment of Coronary Stenosis Following PCI

Completed
Conditions
Angina, Unstable
Coronary Stenosis
Angina, Stable
Coronary Artery Disease
Interventions
Diagnostic Test: iFR pullback
Registration Number
NCT03084367
Lead Sponsor
Volcano Corporation
Brief Summary

This is a pilot study designed to assess the relationship between iFR (instantaneous wave-free ratio) pullback and the distribution of coronary atheroma/stenoses as assessed by Quantitative Coronary Angiography (QCA) post angiographically successful PCI (Percutaneous Coronary Intervention).

Detailed Description

DEFINE-PCI is a multi-center, prospective, non-significant risk study in up to 25 centers in USA and internationally. Consented subjects with CAD (Coronary Artery Disease) who undergo physiologic lesion assessment with iFR\<0.90 in at least 1 coronary artery are eligible for participation. After successful PCI to all culprit lesions based on angiographic assessment of the treating physician, a blinded post-PCI iFR and iFR pullback will be performed. The proportion of patients with impaired post-PCI iFR will be assessed, and the number of patients in whom ischemia could theoretically be normalized with further PCI determined. Additionally, the association between the post-PCI iFR results and cardiovascular events and clinical symptoms will be assessed. Follow-up will be at 1, 6 and 12 months, including administration of quality of life questionnaires.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
500
Inclusion Criteria
  1. Subject must be > 18 years old
  2. Subjects presenting with stable angina, silent ischemia or non-ST-elevation ACS (acute coronary syndrome) (unstable angina or biomarker positive)
  3. Single vessel CAD with at least 2 separate lesions (≥10 mm apart) of ≥40% stenosis or a single long lesion of ≥20mm OR multi-vessel CAD, defined as at least 2 vessels with ≥40% stenosis
  4. Pre-PCI iFR performed in all vessels intended for PCI
  5. Pre-PCI iFR of <0.90 of at least 1 stenosis
  6. Subjects are able and willing to comply with scheduled visits and tests and to provide informed consent.
Exclusion Criteria
  1. Pregnant or planning to become pregnant for the duration of the study
  2. Acute STEMI (ST-elevated Myocardial Infarction) within the past 7 days
  3. Cardiogenic shock (sustained (>10 min) systolic blood pressure < 90 mmHg in absence of inotropic support or the presence of an intra-aortic balloon pump).
  4. Ionotropic or temporary pacing requirement
  5. Sustained ventricular arrhythmias
  6. Prior CABG (Coronary Artery Bypass Graft)
  7. Known ejection fraction ≤30%
  8. Chronic Total Occlusion (CTO)
  9. Known severe mitral or aortic stenosis.
  10. Any known medical comorbidity resulting in life expectancy < 12 months.
  11. Participation in any investigational study that has not yet reached its primary endpoint.
  12. Known severe renal insufficiency (eGFR <30 ml/min/1.72 m2).
  13. TIMI flow <3 at baseline
  14. Intra-coronary thrombus on baseline angiography

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
iFR post angiographically successful PCIiFR pullback-
Primary Outcome Measures
NameTimeMethod
Number of Participants With Residual Ischemia (iFR <0.90)end of procedure/intervention

Residual ischemia is defined as iFR measurement \<0.90 after operator-assessed angiographically successful PCI (residual diameter stenosis \<50% in any treated lesion in the target vessel) This outcome describes the number of participants that had a residual ischemia (defined as iFR\<0.90) after a PCI that appeared to be successful based on angiography.

Secondary Outcome Measures
NameTimeMethod
Recurrent Ischemia12 month

Recurrent ischemia at one-year

Target Vessel Revascularization12 month

Ischemia-driven target vessel revascularization at one year

DifferentiationEnd of procedure /intervention

Differentiation of the cause for impaired iFR

Delta iFRat the end of the procedure/intervention

Predictors of delta iFR before and after PCI, or predictors of impaired iFR Outcome is presented as the odds ratio (OR) that the post-PCI iFR will be \<0.90. An OR \> 1 means greater odds that the post-PCI iFR is \<0.90, OR = 1 means there is no association, and OR \< 1 means there is a lower odds that the post-PCI iFR is \<0.90.

Target Vessel MI12 month

Target vessel Myocardial infarction at one year

Correlation Between iFR and Angiographic Visual Interpretationat the end of the procedure/intervention

Correlation between iFR \<0.90 and coronary stenosis \>50% assessed by visual interpretation.

This was tested using generalized estimating equations for logistic regression to account for the correlation of observations from the same subject.

An absolute value of exactly 1 implies that a linear equation describes the relationship between iFR and visual interpretation of the angiography.

Outcome reports how well the iFR value and the visual interpretation are in agreement (for example, when iFR \<0.90 and coronary stenosis \>50% assessed by visual interpretation the correlation is 1).

Target Vessel Failure12 months

Target vessel failure defined as cardiac death, target vessel myocardial infarction, ischemia-driven target vessel revascularization

Quality of Life Change From Baseline to 12 Months Follow-up12 months

Quality of life (assessed by the Seattle Angina Questionnaire) at baseline, 30-days, 6 months and 1 year (12 months).

Minimum score is 0 and maximum score is 100, with a high score representing a more positive quality of life score.

Outcome is the change in score from baseline to 12 months follow-up.

Cardiac Mortality12 months

All-cause and cardiac mortality at one year

Number of Participants in Which the iFR Would Become Non-significant if a Focal Stenosis Demonstrated by iFR Pullback Were Treated With PCIProcedural

Number of participants in which the iFR would become non-significant if a focal stenosis demonstrated by iFR pullback were treated with PCI

Cardiac Events12 months

Composite endpoint of cardiac death, target vessel myocardial infarction, ischemia-driven target vessel revascularization or recurrent ischemia at one year after PCI

Trial Locations

Locations (28)

VA Medical Center

🇺🇸

Long Beach, California, United States

Vidant Medical Center

🇺🇸

Greenville, North Carolina, United States

Wellmont CVA Heart Insitute

🇺🇸

Kingsport, Tennessee, United States

VA North Texas Health Care

🇺🇸

Dallas, Texas, United States

Emory University Hospital

🇺🇸

Atlanta, Georgia, United States

Atlanta VA Medical Center

🇺🇸

Decatur, Georgia, United States

Northshore Hospital

🇺🇸

Manhasset, New York, United States

Minneapolis Heart Institute

🇺🇸

Minneapolis, Minnesota, United States

Colorado Heart and Vascular

🇺🇸

Lakewood, Colorado, United States

Rockford CV Associates

🇺🇸

Rockford, Illinois, United States

Midwest Cardiovascular Research Foundation

🇺🇸

Davenport, Iowa, United States

Baystate Medical Center

🇺🇸

Springfield, Massachusetts, United States

Dartmouth Hitchcock

🇺🇸

Lebanon, New Hampshire, United States

South Side Hospital

🇺🇸

Bay Shore, New York, United States

Columbia University Medical Center/NewYork Presbyterian Hospital

🇺🇸

New York, New York, United States

St Francis Hospital

🇺🇸

Roslyn, New York, United States

New York Presbyterian Hospital -Weill Cornell

🇺🇸

New York, New York, United States

SUNY- Stony Brook

🇺🇸

Stony Brook, New York, United States

Lenox Hill Hospital

🇺🇸

New York, New York, United States

Duke University Hospital

🇺🇸

Durham, North Carolina, United States

Miriam Hospital

🇺🇸

Providence, Rhode Island, United States

Basildon Univeristy Hospital

🇬🇧

Basildon, United Kingdom

Aurora St Lukes Medical Center

🇺🇸

Milwaukee, Wisconsin, United States

VU University Medical Center

🇳🇱

Amsterdam, Netherlands

AMC Amsterdam

🇳🇱

Amsterdam, Netherlands

Royal Bournemouth hospital

🇬🇧

Bournemouth, United Kingdom

Royal Devon & Exeter NHS Foundation Trust

🇬🇧

Exeter, United Kingdom

Imperial College of London- Hammersmith Hospital

🇬🇧

London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath